Skip to content

RetaLac® is a co-processed excipient of 50 % hypromellose (HPMC 2208) and 50 % milled alpha-lactose monohydrate, specifically designed for direct compression and dry granulation of modified release formulations.

While a binary composition, RetaLac® is monoparticulate in structure, having hypromellose and lactose in each particle. It is characterized by superior functional performance such as improved flow and blendability. Additionally, due to its monoparticulate structure, RetaLac® possesses both plastic and brittle fracture deformation characteristics, enhancing compactibility in direct compression (DC) compared to traditional wet granulation and physical admixtures of the parent ingredients.

API release is controlled predominantly by diffusion through the hydrophilic matrix, and is most robust in the range of pH 1.0 to 7.4. To minimize development time, API dissolution prediction as a function of tablet geometry is possible. This is aided by RetaLac®’s dramatic improvement in wettability compared to HPMC alone or in traditional wet granulations and simple admixtures.

Benefits

  • Direct compression of modified release formulations
  • Superior processability compared to corresponding wet granulated and physical admixture of parent ingredients
  • Dissolution can be quantitatively predicted as a function of tablet geometry
  • Drug release from hydrophilc matrix is governed by diffusion and is very robust within a pH range of 1.0–7.4
  • RetaLac®, exhibiting monoparticulate structure, provides plastic deformation behavior and brittle fracture as well, which leads to overall improved compactibility
  • Dramatic improvement in wettability compared to pure hypromellose

Areas of Application

  • Capsule filling
  • Direct compression (suitable for multi-layer and mini tablets as well)
  • Dry granulation
  • Preparation of aqueous HPMC formulations
  • Extrusion, spheronization

Order your free sample!

Add to cart
  • Dry granulation
  • Direct compression
  • Roller compaction
  • Co-processed Excipients
  • Oral Solid Dose
  • Multi-unit tablet
  • Mini tablet
  • Sustained release tablet
  • Placebo tablet
  • Low to medium dose DC formulation
  • Extrusion-spheronization
  • Capsule
  • Tablet

12kg – Plastic drum with PE-EVOH-PE inliner

24 months

Wasserburg am Inn, Germany

Downloads

Order Specifications

Show documents in all languages.

Order Material Safety Data Sheets

Show documents in all languages.

Typical particle size distribution

Typical Product Data

  • x10: 61 µm, x50: 158 µm, x90: 337 µm
  • Span [(x90-x10)/x50]: 1.74
  • Density bulk: 0.267 g/ml
  • Density tapped: 0.355 g/ml
  • Hausner Ratio: 1.33
  • Carr’s Index: 25 %

Specified Product Data

Particle size distribution

Sieve Method: Mechanical sieve shaker

  • <32 µm: NMT 15%
  • <250 µm: NLT 80%

Not found the right product yet?
Do you need…

Cellactose® 80 and MicroceLac® 100 enable high API load with excellent content uniformity – ideal for challenging formulations.

MicroceLac® Plus combines lactose and MCC for exceptional tabletability. It outperforms conventional excipients – even with high drug loads.

StarLac® combines lactose and starch to support the development of soft tablets with fast disintegration – ideal for ODT formulations.

CombiLac® combines lactose, cellulose, and starch to enable the production of hard tablets with fast disintegration – ideal for robust and effective formulations.

We are experts in co-processed excipients – feel free to contact us for your custom formulation needs.

Looking for a customized lactose solution? We develop tailored formulations in close collaboration with you, ensuring full compliance with your specific requirements.

Use our Product Finder to compare all MEGGLE Excipients and identify the best match for your needs.

Do you have any questions or need a customised solution?